Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-78898A · 1 trial · 1 indication
The thickness of the retina was measured using a non-invasive device that produces cross-sectional and 3D images of the eye. The reduction was calculated by subtracting Week 4 visit value from the Baseline value. A positive number indicates a reduction in thickness compared to baseline, whereas a negative number indicates an increase in thickness. An increase in thickness as compared to baseline may indicate a progression of the underlying disease.
An ESI was a protocol-specified event of scientific and medical concern specific to the Sponsor's product or program where ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. These adverse events could have been serious or nonserious and may have required further investigation in order to characterize and understand.
| Arm | Type | Description |
|---|---|---|
| AL-78898A | EXPERIMENTAL | Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up |
| Lucentis | ACTIVE_COMPARATOR | Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up |
| Name | Type | Description |
|---|---|---|
| AL-78898A | DRUG | Investigational treatment |
| Ranibizumab | DRUG | Anti-vascular endothelial growth factor (VEGF) treatment |
Inclusion Criteria: * Willing to give informed consent, make the required study visits and follow instructions; * Newly diagnosed with exudative age-related macular degeneration (AMD); * Presence of primary juxta- or subfoveal choroidal neovascularization (CNV) secondary to AMD (study eye); * Best-...
AL-78898A is an investigational small molecule being studied for the treatment of exudative age-related macular degeneration, a condition that causes abnormal blood vessel growth and fluid leakage in the retina, leading to vision loss. It is currently in clinical development and has not been approved by regulatory authorities.
AL-78898A is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is a global medical device and pharmaceutical company focused on eye care, and it is conducting clinical research on this investigational therapy for exudative age-related macular degeneration.
AL-78898A is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it has not yet received approval from the U.S. Food and Drug Administration or other regulatory bodies for commercial use.
AL-78898A has one completed Phase 2 clinical trial registered under the identifier NCT01157065. This trial, titled 'Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration,' enrolled 99 participants in the United States and was a randomized, double-blind, active-controlled study.
No alternative names for AL-78898A have been reported in clinical trial records. The drug is identified solely by its code name AL-78898A in the completed Phase 2 study for exudative age-related macular degeneration.